May 22, 2020 8:23 AM
Forget about COVID-19, Kenya and indeed the rest of the world has indeed been severely affected by HIV/AIDS for the last 3 decades or so. Scientific research to find a cure has ended in futility. However, there is light at the end of the tunnel after scientists made this vital Breakthrough
Photo/Courtesy
As reported by the Daily nation, scientists from a pharmaceutical company called ViiV healthcare have prematurely terminated a study of a 2- month long injectable HIV pre-exposure drug (PrEP) after discovering that the new injectable drug is very effective in preventing HIV infections.
Currently, HIV negative people at risk of contracting HIV take a daily dose of PrEP pills which are basically a type of ARVs and they have proved difficult for most users. This is set to change with the latest Discovery.
Photo/Courtesy
The early termination of tests on the new injectable drug called Cabotegravir (CAB) has been hailed by scientists as a game changer in HIV PrEPS and HIV prevention at large. In the trial, CAB injectable drug stopped 69% more HIV infections as compared to Truvada pills (the current most used PrEP pills)
"It is really exciting, it gives another option for people who can't or don't want to take daily pills," Jared Baeten, an epidemiologist at the University of Washington Seattle who was not involved in the study but is a HIV PrEP expert told Science Magazine.
Photo/Courtesy
This is indeed music in the ears to many Kenyans and there is hope that the more than 1.6 million number of Kenyans living with HIV will remain constant and new infections will be prevented. The good news is that HIV negative people at high risk of contracting HIV will only have to take one injection once every two months!
No comments:
Post a Comment